Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FORGOTTEN HISTORY: Verona pharma | History Defined

Merck Just Made a Big Bet on a New Cancer Growth Engine

Merck's $6.7 billion Terns acquisition bolsters its oncology pipeline while reinforcing its strong margins, steadily growing dividend, and long-term growth.

This Blue-Chip Dividend Stock Is Stuck in the Tariff Crosshairs. Can Cost Cuts Save the Day?

This Blue-Chip Dividend Stock Is Stuck in the Tariff Crosshairs. Can Cost Cuts Save the Day?

Merck faces intense pressure from new global tariffs and a looming Keytruda patent expiration, but is fighting back with a $3 billion cost-cutting plan and a $10 billion push into new therapies —moves that analysts say could revive the shares if executed well.

1 Blue-Chip Dividend Stock That Still Has Room to Run

1 Blue-Chip Dividend Stock That Still Has Room to Run

This pharmaceutical leaders offers a combination of growth, income, and innovation.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday

U.S. stocks were higher, with the Dow Jones index gaining around 0.1% on Wednesday.

Up 515%, Watch This Biopharma Breakout

Verona Pharma (VRNA) is showing exceptional technical strength, hitting a new high in morning trading on June 24. The stock has a 100% technical “Buy” signal via Barchart. The stock has surged 515% over the past year, with Trend Seeker and moving averages confirming the bullish trend. Fundamentals are robust...

Verona Pharma Keeps Hitting New Highs

Summary Verona Pharma (VRNA) shows strong technical indicators with a 54.89% gain since 11/19, driven by Barchart's Trend Seeker buy signal. The company focuses on developing ensifentrine for respiratory diseases, currently in Phase 3 trials, with multiple inhaler formulations. Barchart's technical indicators highlight 100% buy signals, a 222.12% gain in...

2 Standout Biotech Stocks With 32% to 63% Upside

A strong pipeline of products could potentially transform these companies, but there are risks.

inkl

Read news from The Economist, FT, and more,
with one subscription

Benzinga's Top Ratings Upgrades, Downgrades For August 26, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 26, 2022

Recap of Tuesday's Biotech Catalysts - End Of the Day Summary

Recap of Tuesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Relmada Therapeutics’ (NASDAQ:RLMD) lead asset REL-1017 as a monotherapy for the treatment major depressive disorder (MDD). Relmada shares traded in a range of $26.02 to $27.96 on a day volume of 173.79 thousand shares, closed regular trading…

Recap: Verona Pharma Q1 Earnings

Recap: Verona Pharma Q1 Earnings

Verona Pharma (NASDAQ:VRNA) reported its Q1 earnings results on Tuesday, May 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Verona Pharma Q1 2022 Earnings Conference Call On May 3, 2022 At 09:00 AM ET

Verona Pharma Q1 2022 Earnings Conference Call On May 3, 2022 At 09:00 AM ET

Verona Pharma (NASDAQ:VRNA) will host a conference call at 09:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. How to Attend Verona Pharma (VRNA) Conference Call Follow this link to access the live webcast.

Verona Pharma: Q4 Earnings Insights

Verona Pharma: Q4 Earnings Insights

Verona Pharma (NASDAQ:VRNA) reported its Q4 earnings results on Thursday, March 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

1

Organisations

Food and Drug Administration

B of A Securities

US Food and Drug Administration

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

363,548 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play